Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,600.00
Bid: 1,570.00
Ask: 1,695.00
Change: 0.00 (0.00%)
Spread: 125.00 (7.962%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,600.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London pre-open: FTSE to open marginally higher

Tue, 12th Nov 2013 06:59

City sources predict the FTSE 100 will open around two points higher than yesterday's close of 6,728.37, tracking modest gains seen in the US last night and ahead of today's inflation figures.US markets ended slightly higher yesterday, with the Dow Jones Industrial Average hitting another record close, extending recent gains despite increased speculation surrounding the impending taper of quantitative easing.Today, all eyes will turn to German and UK inflation. Germany's consumer price index (CPI) is expected to remain unchanged at 1.2% in October. UK inflation is predicted to fall to 2.5% in October from 2.7% a month earlier. It will come a day ahead of the Bank of England's quarterly inflation report which will be watched closely to see if the central bank upgrades its economic forecasts. A change in economic projections could set the stage for bringing forward the expected date of its first interest rate hike.In other news, Energy Secretary Ed Davey is today expected to say that energy customers are not "cash cows" that can be "squeezed" to earn higher profits for shareholders. The Liberal Democrat Minister is set to urge businesses in the industry to become more transparent about exactly how they are tackling rising bills. CRH delivers modest Q3 rise in sales In this morning's company news, building materials giant CRH reported a small increase in like-for-like (LFL) sales in the third quarter, a strong turnaround after difficult weather conditions hit revenues in the first half. LFL sales in the three months to the end of September improved by 2% across the group, following a 6% decline in the first six months of the year. Overall sales revenue totalled €5.4bn during the period, some 2% ahead of the €5.3bn reported the year before.Babcock International Group has lifted its dividend by 10% to 6.9p due to a strong first half and a positive outlook. The engineering support services company achieved pre-tax profit of £105.9m in the six months through September, up 32% on the previous year's £80.4m.Real estate giant Land Securities posted improved revenue profit and net asset value (NAV) during the six months ended September 30th and said it is confident of delivering future progress. The UK's largest commercial property firm said basic NAV per share rose to 994p in the period from 959p a year earlier. Revenue profit rose to 8.9% to £156.5m.GlaxoSmithKline's heart disease drug, darapladib, has missed a key milestone in its development. The group said it would continued to investigate the darapladib inhibitor and would work to better understand the data, including evaluation of the patient sub-groups, and await the outcome of a second Phase III study of darapladib in acute coronary syndrome to help it determine its next stage of work. Monday's big moversYesterday, in a major blow to BSkyB and ITV, telecoms group BT confirmed that it has won the exclusive rights to broadcast live the UEFA Champions League and UEFA Europa League for three seasons. RSA Insurance was also a heavy faller after saying that "issues in the Irish claims and finance functions" were found during a routine internal audit, leading to the suspension of its Ireland Chief Executive Officer (CEO) and two of his senior executives. NR
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.